Decentralization, AI, and Gene Editing are Opportunities for CGT Contractors
CDMOs already play a critical role in the cell and gene therapy development and manufacturing space and, says Rose Biosolutions, with emerging bioprocessing technologies, production methods, and strategies, are creating even more opportunities for contractors. The post Decentralization, AI, and Gene Editing are Opportunities for CGT Contractors appeared first on GEN - Genetic Engineering and…
Decentralization, artificial intelligence (AI) process modeling, and advancements in gene editing are creating new opportunities for third-party contractors in the cell and gene therapy (CGT) industry. With 66% to 90% of CGT production outsourced to external manufacturers, contractors bring valuable expertise that developers lack.
Alan Smith, PhD, global head of innovation at Rose Biosolutions, explains that highly experienced CDMOs offer broad experience and mastery of manufacturing, quality, and regulatory strategy. Trust and intimacy are key in building strong relationships with partner developers. Quality control expertise is crucial for limiting product quality risks in the logistics chain.
Decentralized manufacturing models, where therapies are produced close to recipients, are emerging to minimize transportation needs and enable local production. CDMOs can position themselves to meet the manufacturing requirements of decentralized paradigms, leveraging product manufacture expertise, quality elements, and expedited release strategies for safe and effective delivery preparations.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
